OTSUKA AMERICA PHARMACEUTICAL, INC. for OTSUKA AMERICA PHARMACEUTICAL, INC.
What was lobbied
5 issue areas, each in the filer's own words, with who lobbied on it and where.
Budget/Appropriations BUD
Appropriations for the Department of Health & Human Services and the Department of Veterans Affairs, and Department of Defense.
Foreign entity interest: Otsuka (Japan), identified on filer's Registration Statement (LD-1), as its parent organization has an interest in the listed issues.
| Lobbyist | Covered position, as disclosed |
|---|---|
| THOMAS FOULKES | — |
| ISABEL OMER | — |
| AMELIA SUERMANN | — |
Veterans VET
Health care policies relating to mental health and PTSD, including authorizations and appropriations for the Department of Veterans Affairs related to mental health and PTSD.
Foreign entity interest: Otsuka (Japan), identified on filers Registration Statement (LD-1), as its parent organization has an interest in the listed issues.
| Lobbyist | Covered position, as disclosed |
|---|---|
| THOMAS FOULKES New | — |
| ISABEL OMER | — |
| AMELIA SUERMANN | — |
Medicare/Medicaid MMM
Implementation of the Inflation Reduction Act. Issues related to Medicare Part D redesign's impact on low-income subsidy beneficiaries. Issues related to prior authorization, open access, and medication step therapy; The Safe Step Act (HR 5509/S. 2903)
Foreign entity interest: Otsuka (Japan), identified on filer's Registration Statement (LD-1), as its parent organization has an interest in the listed issues.
| Lobbyist | Covered position, as disclosed |
|---|---|
| THOMAS FOULKES | — |
| ISABEL OMER | — |
| AMELIA SUERMANN | — |
Health Issues HCR
Issues relating to early detection of PTSD, mental health parity and coordinated care and mental health equity. PBM reform. Issues related to rare nephrology/kidney diseases, 340B reform, psychedelics treatments for PTSD and mental health. H.R. 1518, the New Era of Preventing End-Stage Kidney Disease Act. Issues related to drug pricing, foreign reference pricing, biomedical research, and pharmaceutical supply chain.
Foreign entity interest: Otsuka (Japan), identified on filer's Registration Statement (LD-1), as its parent organization has an interest in the listed issues.
| Lobbyist | Covered position, as disclosed |
|---|---|
| THOMAS FOULKES | — |
| ISABEL OMER | — |
| AMELIA SUERMANN | — |
Tariff (miscellaneous tariff bills) TAR
Issues related to tariffs on pharmaceuticals and pharmaceutical supply chain.
Foreign entity interest: Otsuka (Japan), identified on filers Registration Statement (LD-1), as its parent organization has an interest in the listed issues.
| Lobbyist | Covered position, as disclosed |
|---|---|
| THOMAS FOULKES | — |
| ISABEL OMER | — |
| AMELIA SUERMANN | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.